ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous Priming Antigen-inducible Anti-PSMA CAR T-cells AB-3028

Its studies are mostly in Prostatic Neoplasms, led by Arsenal Biosciences.

Furthest: phase 2, since Dec 10, 20251 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arsenal Biosciences10 open or runningphase 2since Dec 10, 2025Dec 10, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 10, 2025First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT07285694 · 3 enrolled · United States

TargetBeta

“A preparation of autologous T-lymphocytes that have been modified to encode a genetic circuit consisting of a priming receptor that induces the expression of a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) upon binding to an”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07285694Prostatic Neoplasms · United States2TerminatedOct 19, 20263

How it is read

Names in the registry

  • “AB-3028”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.